Demonstrates enhanced anti-tumor effects in pancreatic ductal adenocarcinoma via nanocarriers with ultrasound stimulation.
Pancreatic ductal adenocarcinoma (PDAC), a refractory cold tumor, is characterized by a dense extracellular matrix (ECM) and stress-triggered neuroimmune crosstalk, which cause T cell exhaustion and poor efficacy of anti-T cell immunoglobulin and mucin domain-3 antibody (aTIM-3) monotherapy. Here, we report a sucrose-hybridized, Pan02 pancreatic tumor cell membrane-coated ultrasound (US)-responsive biomimetic nanocarrier (CT@SM) co-loading carvedilol (β-blocker) and aTIM-3. The Pan02 tumor cell membrane shell enables homologous tumor targeting, prolonged circulation, and reduced off-target distribution, while intercalated sucrose modulates vesicle acoustic impedance to generate US-triggered inertial cavitation. US activates cavitation to disrupt the ECM and co-releases cargos deep in tumors: carvedilol relieves norepinephrine-mediated T cell exhaustion, and aTIM-3 suppresses M2-type tumor-associated macrophages. Consequently, compared to free aTIM-3, up to an 11.23-fold increase of aTIM-3 in the tumor region was obtained in the CT@SM + US group. Immunotherapy efficacy was significantly enhanced by reactivating T cells, leading to suppressed tumor growth and prolonged survival in the PDAC mice stress model. Overall, this study offers a promising strategy based on a dual-modified biomimetic acoustic delivery platform for immunotherapy in PDAC and other cold tumors.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: